Cape Cod Five Cents Savings Bank Trims Holdings in ResMed Inc. (RMD)

Cape Cod Five Cents Savings Bank reduced its position in shares of ResMed Inc. (NYSE:RMD) by 2.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 45,902 shares of the medical equipment provider’s stock after selling 1,006 shares during the quarter. Cape Cod Five Cents Savings Bank’s holdings in ResMed were worth $3,887,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Baillie Gifford & Co. increased its holdings in ResMed by 0.9% during the 3rd quarter. Baillie Gifford & Co. now owns 4,913,626 shares of the medical equipment provider’s stock worth $378,154,000 after purchasing an additional 44,340 shares during the period. Congress Asset Management Co. MA increased its holdings in ResMed by 2.2% during the 4th quarter. Congress Asset Management Co. MA now owns 1,078,645 shares of the medical equipment provider’s stock worth $91,350,000 after purchasing an additional 23,714 shares during the period. Legal & General Group Plc increased its holdings in ResMed by 0.7% during the 3rd quarter. Legal & General Group Plc now owns 765,271 shares of the medical equipment provider’s stock worth $58,892,000 after purchasing an additional 5,169 shares during the period. Schwab Charles Investment Management Inc. increased its holdings in ResMed by 4.3% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 689,671 shares of the medical equipment provider’s stock worth $58,409,000 after purchasing an additional 28,691 shares during the period. Finally, American Capital Management Inc. increased its holdings in ResMed by 0.6% during the 4th quarter. American Capital Management Inc. now owns 660,818 shares of the medical equipment provider’s stock worth $55,965,000 after purchasing an additional 3,976 shares during the period. Institutional investors own 61.41% of the company’s stock.

Shares of ResMed Inc. (RMD) opened at $91.05 on Monday. The stock has a market capitalization of $12,920.00, a price-to-earnings ratio of 45.75 and a beta of 0.92. ResMed Inc. has a 52-week low of $67.04 and a 52-week high of $104.78.

ResMed (NYSE:RMD) last announced its earnings results on Monday, January 22nd. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.22. The business had revenue of $601.27 million for the quarter, compared to analysts’ expectations of $583.77 million. ResMed had a return on equity of 22.75% and a net margin of 12.98%. The business’s revenue for the quarter was up 13.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.73 EPS. equities analysts predict that ResMed Inc. will post 3.34 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 15th. Shareholders of record on Thursday, February 8th will be given a dividend of $0.35 per share. The ex-dividend date is Wednesday, February 7th. This represents a $1.40 annualized dividend and a yield of 1.54%. ResMed’s dividend payout ratio (DPR) is presently 70.35%.

RMD has been the topic of several research reports. Needham & Company LLC restated a “sell” rating on shares of ResMed in a report on Friday, October 27th. Zacks Investment Research cut ResMed from a “buy” rating to a “sell” rating in a research report on Tuesday, October 24th. BMO Capital Markets increased their target price on ResMed from $70.00 to $74.00 and gave the company a “market perform” rating in a research report on Friday, October 27th. JPMorgan Chase & Co. increased their target price on ResMed from $72.00 to $73.00 and gave the company an “overweight” rating in a research report on Monday, October 30th. Finally, Barclays increased their target price on ResMed from $68.00 to $70.00 and gave the company an “underweight” rating in a research report on Friday, October 27th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $76.00.

In other news, insider James Hollingshead sold 7,019 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $84.16, for a total value of $590,719.04. Following the completion of the sale, the insider now owns 66,409 shares of the company’s stock, valued at approximately $5,588,981.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Brett Sandercock sold 1,250 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $85.36, for a total value of $106,700.00. Following the completion of the sale, the chief financial officer now directly owns 79,572 shares of the company’s stock, valued at approximately $6,792,265.92. The disclosure for this sale can be found here. Insiders have sold a total of 49,802 shares of company stock worth $4,824,727 in the last ninety days. Insiders own 1.77% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Cape Cod Five Cents Savings Bank Trims Holdings in ResMed Inc. (RMD)” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://ledgergazette.com/2018/02/12/cape-cod-five-cents-savings-bank-trims-holdings-in-resmed-inc-rmd.html.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply